Identification of immunity-related genes in prostate cancer and potential role of the ETS family of transcription factors in their regulation

International Journal of Molecular Medicine

Volumn 28, Issue 5, 2011, Pages 799-807

  Adler, David ^a   Lindstrot, Andreas ^a   Ellinger, Jörg ^a   Rogenhofer, Sebastian ^a   Buetner, Reinhard ^a   Wernert, Nicolas ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

B cell; ETS; Immunity; Innate; Prostate; T cell; Transcriptional regulation

Indexed keywords

ADENOSINE A1 RECEPTOR; ALPHA4 INTEGRIN; ANTINEOPLASTIC AGENT; ARACHIDONATE 15 LIPOXYGENASE; CD38 ANTIGEN; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYSTEINE RICH SECRETORY PROTEIN 3; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; HISTONE DEACETYLASE; HISTONE DEACETYLASE 9; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5; LACTOFERRIN; PEPTIDOGLYCAN RECOGNITION PROTEIN; PEPTIDOGLYCAN RECOGNITION PROTEIN 1; PROTEIN SH2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; SECRETORY PROTEIN; SH2 DOMAIN PROTEIN 1A; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DOWN REGULATION; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; LASER MICRODISSECTION; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROSTATE CARCINOMA; PROSTATECTOMY; RNA EXTRACTION; UPREGULATION;

EID: 80053092849     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.771     Document Type: Article

References (93)

1. Kumar-Sinha C, Tomlins SA and Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8: 497-511, 2008.
2. Richardson AM, Woodson K, Wang Y, et al: Global expression analysis of prostate cancer-associated stroma and epithelia. Diagn Mol Pathol 16: 189-197, 2007. (Pubitemid 350196975)
3. Arora R, Koch MO, Eble JN, Ulbright TM, Li L and Cheng L: Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100: 2362-2366, 2004. (Pubitemid 38657883)
4. Ruijter ET, Van de Kaa CA, Schalken JA, Debruyne FM and Ruiter DJ: Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 180: 295-299, 1996. (Pubitemid 26393679)
5. Hsu DS, Kim MK, Balakumaran BS, et al: Immune signatures predict prognosis in localized cancer. Cancer Invest 28: 765-773, 2010.
6. Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183, 2007.
7. Webster WS, Small EJ, Rini BI and Kwon ED: Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol 23: 8262-8269, 2005. (Pubitemid 46211564)
8. Nelson WG, De Marzo AM, DeWeese TL and Isaacs WB: The role of inflammation in the pathogenesis of prostate cancer. J Urol 172: 6-12, 2004.
9. + lymphocytes modulate prostate cancer progression in mice. Int J Cancer 125: 868-878, 2009.
10. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A and Thompson TC: Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 60: 5857-5861, 2000.
11. Vesalainen S, Lipponen P, Talja M and Syrjanen K: Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 30A: 1797-1803, 1994. (Pubitemid 24377155)
12. Pellat-Deceunynck C: Tumour-associated antigens in multiple myeloma. Br J Haematol 120: 3-9, 2003.
13. Minenkova O, Pucci A, Pavoni E, et al: Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int J Cancer 106: 534-544, 2003. (Pubitemid 36966210)
14. Stockert E, Jager E, Chen YT, et al: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187: 1349-1354, 1998. (Pubitemid 28189124)
15. Bradford TJ, Wang X and Chinnaiyan AM: Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 24: 237-242, 2006.
16. Rajarubendra N, Lawrentschuk N, Bolton DM, Klotz L and Davis ID: Prostate cancer immunology - an update for Urologists. BJU Int 107: 1046-1051, 2011.
17. Joshua AM, Evans A, Van der Kwast T, et al: Prostatic preneoplasia and beyond. Biochim Biophys Acta 1785: 156-181, 2008.
18. Cai C, Hsieh CL, Omwancha J, et al: ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 21: 1835-1846, 2007. (Pubitemid 47173795)
19. Gallant S and Gilkeson G: ETS transcription factors and regulation of immunity. Arch Immunol Ther Exp 54: 149-163, 2006.
20. Hollenhorst PC, Jones DA and Graves BJ: Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res 32: 5693-5702, 2004. (Pubitemid 39545685)
21. Wasylyk B, Hahn SL and Giovane A: The Ets family of transcription factors. Eur J Biochem 211: 7-18, 1993. (Pubitemid 23039491)
22. Hollenhorst PC, Shah AA, Hopkins C and Graves BJ: Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 21: 1882-1894, 2007.
23. Wang CY, Petryniak B, Ho IC, Thompson CB and Leiden JM: Evolutionarily conserved Ets family members display distinct DNA binding specificities. J Exp Med 175: 1391-1399, 1992.
24. Oikawa T: ETS transcription factors: possible targets for cancer therapy. Cancer Sci 95: 626-633, 2004.
25. Hashiya N, Jo N, Aoki M, et al: In vivo evidence of angiogenesis induced by transcription factor Ets-1: Ets-1 is located upstream of angiogenesis cascade. Circulation 109: 3035-3041, 2004.
26. Rothhammer T, Hahne JC, Florin A, et al: The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci 61: 118-128, 2004. (Pubitemid 38121905)
27. Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F and Wernert N: Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene 24: 5384-5388, 2005.
28. He J, Pan Y, Hu J, Albarracin C, Wu Y and Dai JL: Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther 6: 76-82, 2007. (Pubitemid 46294180)
29. Wellmann A, Wollscheid V, Lu H, et al: Analysis of microdissected prostate tissue with ProteinChip® arrays - a way to new insights into carcinogenesis and to diagnostic tools. Int J Mol Med 9: 341-347, 2002.
30. Okuducu AF, Janzen V, Hahne JC, Ko Y and Wernert N: Influence of histochemical stains on quantitative gene expression analysis after laser-assisted microdissection. Int J Mol Med 11: 449-453, 2003.
31. Okuducu AF, Hahne JC, Von Deimling A and Wernert N: Laser-assisted microdissection, techniques and applications in pathology (Review). Int J Mol Med 15: 763-769, 2005.
32. Cold Spring Harbor Laboratory: Transcriptional Regulatory Element Database, available at http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process=home, accessed in 2011.
33. TFSEARCH: Searching Transcription Factor Binding Sites. Available at http://www.cbrc.jp/research/db/TFSEARCH.html accessed in 2011.
34. Heinemeyer T, Wingender E, Reuter I, et al: Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362-367, 1998. (Pubitemid 28295292)
35. Okamoto S, Ji H, Howie D, et al: Expression of the SH2D1A gene is regulated by a combination of transcriptional and posttranscriptional mechanisms. Eur J Immunol 34: 3176-3186, 2004. (Pubitemid 39549396)
36. Blumenthal SG, Aichele G, Wirth T, Czernilofsky AP, Nordheim A and Dittmer J: Regulation of the human interleukin-5 promoter by Ets transcription factors. Ets1 and Ets2, but not Elf-1, cooperate with GATA3 and HTLV-I Tax1. J Biol Chem 274: 12910-12916, 1999.
37. Van Dijk TB, Baltus B, Raaijmakers JA, Lammers JW, Koenderman L and De Groot RP: A composite C/EBP binding site is essential for the activity of the promoter of the IL3/IL5/granulocyte-macrophage colony-stimulating factor receptor beta c gene. J Immunol 163: 2674-2680, 1999. (Pubitemid 29399192)
38. Van Dijk TB, Baltus B, Caldenhoven E, et al: Cloning and characterization of the human interleukin-3 (IL3)/IL-5/ granulocyte- macrophage colony-stimulating factor receptor betac gene: regulation by Ets family members. Blood 92: 3636-3646, 1998. (Pubitemid 28525189)
39. Milde T, Oehme I, Korshunov A, et al: HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res 16: 3240-3252, 2010.
40. Moreno DA, Scrideli CA, Cortez MA, et al: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol 150: 665-673, 2010.
41. Debniak T, Scott RJ, Huzarski T, et al: CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 65: 835-839, 2005. (Pubitemid 40216442)
42. Mikhalap SV, Shlapatska LM, Yurchenko OV, et al: The adaptor protein SH2D1A regulates signaling through CD150 (SLAM) in B cells. Blood 104: 4063-4070, 2004. (Pubitemid 39620157)
43. Stathopoulos GT, Sherrill TP, Karabela SP, et al: Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med 182: 1273-1281, 2010.
44. Shaheduzzaman S, Vishwanath A, Furusato B, et al: Silencing of lactotransferrin expression by methylation in prostate cancer progression. Cancer Biol Ther 6: 1088-1095, 2007. (Pubitemid 351574961)
45. Mollenhauer J, Wiemann S, Scheurlen W, et al: DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet 17: 32-39, 1997. (Pubitemid 27377529)
46. Mollenhauer J, Herbertz S, Holmskov U, et al: DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer. Cancer Res 60: 1704-1710, 2000. (Pubitemid 30183445)
47. Liu AY, Roudier MP and True LD: Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 165: 1543-1556, 2004. (Pubitemid 39435154)
48. Satterwhite E, Sonoki T, Willis TG, et al: The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood 98: 3413-3420, 2001.
49. Zhang Y, Lu H, Dazin P and Kapila Y: Functional differences between integrin α4 and integrins α5/αv in modulating the motility of human oral squamous carcinoma cells in response to the V region and heparin-binding domain of fibronectin. Exp Cell Res 295: 48-58, 2004. (Pubitemid 38407344)
50. Liu D, Wang X, Zhang Z and Teng CT: An intronic alternative promoter of the human lactoferrin gene is activated by Ets. Biochem Biophys Res Commun 301: 472-479, 2003. (Pubitemid 36279264)
51. Teng CT, Liu Y, Yang N, Walmer D and Panella T: Differential molecular mechanism of the estrogen action that regulates lactoferrin gene in human and mouse. Mol Endocrinol 6: 1969-1981, 1992.
52. Rosen GD, Barks JL, Iademarco MF, Fisher RJ and Dean DC: An intricate arrangement of binding sites for the Ets family of transcription factors regulates activity of the α 4 integrin gene promoter. J Biol Chem 269: 15652-15660, 1994. (Pubitemid 24202157)
53. Kosari F, Asmann YW, Cheville JC and Vasmatzis G: Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev 11: 1419-1426, 2002. (Pubitemid 35340379)
54. Bjartell AS, Al-Ahmadie H, Serio AM, et al: Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 13: 4130-4138, 2007. (Pubitemid 47105975)
55. Lo BK, Yu M, Zloty D, Cowan B, Shapiro J and McElwee KJ: CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol 176: 2435-2446, 2010
56. Amatschek S, Lucas R, Eger A, et al: CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. Br J Cancer 104: 469-479, 2011.
57. Mirza A, Basso A, Black S, et al: RNA interference targeting of A1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis. Cancer Biol Ther 4: 1355-1360, 2005. (Pubitemid 43131180)
58. Liu X, Shin N, Koblish HK, et al: Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115: 3520-3530, 2010.
59. Kuhn DJ and Dou QP: The role of interleukin-2 receptor α in cancer. Front Biosci 10: 1462-1474, 2005.
60. Sashchenko LP, Dukhanina EA, Yashin DV, et al: Peptidoglycan recognition protein tag7 forms a cytotoxic complex with heat shock protein 70 in solution and in lymphocytes. J Biol Chem 279: 2117-2124, 2004. (Pubitemid 38084485)
61. Kang D, Liu G, Lundstrom A, Gelius E and Steiner H: A peptidoglycan recognition protein in innate immunity conserved from insects to humans. Proc Natl Acad Sci USA 95: 10078-10082, 1998.
62. Cho JH, Fraser IP, Fukase K, et al: Human peptidoglycan recognition protein S is an effector of neutrophil-mediated innate immunity. Blood 106: 2551-2558, 2005. (Pubitemid 41510833)
63. Kelavkar UP, Cohen C, Kamitani H, Eling TE and Badr KF: Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. Carcinogenesis 21: 1777-1787, 2000.
64. Hsi LC, Wilson LC and Eling TE: Opposing effects of 15-lipoxygenase- 1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. J Biol Chem 277: 40549-40556, 2002.
65. Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE and Badr KF: Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 22: 1765-1773, 2001.
66. Kim HS, Han HD, Armaiz-Pena GN, et al: Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 17: 1713-1721, 2011.
67. Engl T, Relja B, Blumenberg C, et al: Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 78: 1784-1793, 2006.
68. Fan C, Stendahl U, Stjernberg N and Beckman L: Association between orosomucoid types and cancer. Oncology 52: 498-500, 1995.
69. Irmak S, Tilki D, Heukeshoven J, et al: Stage-dependent increase of orosomucoid and zinc-α2-glycoprotein in urinary bladder cancer. Proteomics 5: 4296-4304, 2005. (Pubitemid 41626097)
70. Funakoshi A and Kono A: Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice. Gastroenterol Jpn 27: 78-82, 1992.
71. Badolato R, Wang JM, Murphy WJ, et al: Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 180: 203-209, 1994. (Pubitemid 24181069)
72. Mattarollo SR and Smyth MJ: A novel axis of innate immunity in cancer. Nat Immunol 11: 981-982, 2010
73. Sung HJ, Ahn JM, Yoon YH, et al: Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 10: 1383-1395, 2011.
74. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, et al: Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem 58: 1015-1023, 2010.
75. Monk PN, Scola AM, Madala P and Fairlie DP: Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 152: 429-448, 2007. (Pubitemid 47585036)
76. Kloth JN, Gorter A, Fleuren GJ, et al: Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol 215: 222-230, 2008.
77. Cimino D, Fuso L, Sfiligoi C, et al: Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. Int J Cancer 123: 1327-1338, 2008.
78. Weeraratna AT, Cajigas JA, Schwartz A, Enquist EG, Manyak MJ and Patierno SR: Loss of uteroglobin expression in prostate cancer: relationship to advancing grade. Clin Cancer Res 3: 2295-2300, 1997. (Pubitemid 28133148)
79. Yoo KH, Kim SK, Chung JH and Chang SG: Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia. Asian J Androl 12: 690-696, 2010.
80. Lim SD, Sun C, Lambeth JD, et al: Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 62: 200-207, 2005. (Pubitemid 40096784)
81. Arnold RS, He J, Remo A, et al: Nox1 expression determines cellular reactive oxygen and modulates c-fos-induced growth factor, interleukin-8, and Cav-1. Am J Pathol 171: 2021-2032, 2007.
82. Fevre-Montange M, Champier J, Durand A, et al: Microarray gene expression profiling in meningiomas: Differential expression according to grade or histopathological subtype. Int J Oncol 35: 1395-1407, 2009.
83. Oster B, Thorsen K, Lamy P, et al: Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer: Mar 11, 2011 (Epub ahead of print).
84. Larrinaga G, Perez I, Sanz B, et al: Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul Pept 165: 218-223, 2010.
85. Zhou L, Zhang R, Yao W, et al: Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. Tohoku J Exp Med 217: 123-131, 2009.
86. Yasui K, Mihara S, Zhao C, et al: Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64: 1403-1410, 2004.
87. Jacobson EM, Hugo ER, Tuttle TR, Papoian R and Ben-Jonathan N: Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol Metab 21: 691-698, 2010.
88. Giuffrida D, Perdichizzi A, Giuffrida MC, et al: Does prolactin induce apoptosis? Evidences in a prostate cancer in vitro model. J Endocrinol Invest 33: 313-317, 2010.
89. Barton K, Muthusamy N, Fischer C, et al: The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 9: 555-563, 1998. (Pubitemid 28499206)
90. Walunas TL, Wang B, Wang CR and Leiden JM: Cutting edge: the Ets1 transcription factor is required for the development of NK T cells in mice. J Immunol 164: 2857-2860, 2000. (Pubitemid 30148940)
91. Biron CA and Brossay L: NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 13: 458-464, 2001. (Pubitemid 32728479)
92. Korbel DS, Finney OC and Riley EM: Natural killer cells and innate immunity to protozoan pathogens. Int J Parasitol 34: 1517-1528, 2004.
93. Wu J and Lanier LL: Natural killer cells and cancer. Adv Cancer Res 90: 127-156, 2003. (Pubitemid 37549223)